TRIM72 Immunohistochemical Expression Can Predict Relapse in Colorectal Carcinoma.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Large bowel adenocarcinoma (colon cancer) has high mortality, especially in advanced stages.
• Current guidelines do not recommend adjuvant chemotherapy for stage I or II colon cancer, yet ~20% of stage II patients recur.
• Predictive tools are needed to identify stage II colon cancer patients at high risk for recurrence.

Purpose of the Study:

• To investigate the predictive value of tripartite motif family protein 72 (TRIM72) immunohistochemical expression in stage II colon cancer.
• To determine if TRIM72 expression can predict recurrence in patients with stage II colon cancer who did not receive adjuvant chemotherapy.

Main Methods:

• Retrospective review of 95 stage II colon cancer patients (microsatellite stable) operated with curative intent.
• Tissue microarray (TMA) construction for immunohistochemical staining of TRIM72.
• Analysis of recurrence rates and correlation with TRIM72 expression after a median follow-up of 17.5 months.

Main Results:

• 31.7% of patients (30/95) recurred.
• Lack of TRIM72 immunohistochemical expression was significantly and independently associated with tumor recurrence.
• Lower TRIM72 expression may indicate a more aggressive tumor phenotype.

Conclusions:

• TRIM72 immunohistochemical analysis is a potential tool to predict recurrence risk in stage II colon cancer.
• Identifying patients with low TRIM72 expression could guide decisions on adjuvant therapy in this controversial setting.
• Further studies in larger cohorts are needed to confirm these findings and refine management strategies.